PATENT APPLICATION Attorney's Docket No: FEE AUTHORIZATION / AMENDMENT TRANSMITTAL LETTER S-225E Filing Date Examiner Group Art Unit Serial No. May 23, 1994 Marianne P. Allen 1817 08/182,183 In Re Application of Lin, et al. For Glial Cell Line-Derived Neurotrophic Factor TO THE ASSISTANT COMMISSIONER FOR PATENTS: Applicant(s) petition(s) for the following extension of time under 37 C.F.R. 1.136(a): One month of original due date (\$110.00) Two months of original due date (\$400.00) Three months of original due date (\$950.00) Four months of original due date (\$1,510.00) A response in connection with the matter for which this extension is requested: is filed herewith. has been filed. ☐ The response is the filing of a continuation application having an express abandonment conditioned on the granting of a filing date to the continuing application. ☐ The accompanying papers include amended claims for which no additional fee is required. The accompanying papers include amended claims the fee for which has been calculated as follows: **CLAIMS AS AMENDED** (6)(3) (1) (2)(4) Claims remaining Highest number No. of extra Additional after amendment previously paid for claims present Rate Fee Minus **Total Claims** x \$22 =\$396.00 122 140 18 Minus x \$82 =\$738.00 Indep. Claims 10 19 9 = ☐ First Appearance of a multiple dependent claim +\$270 Total Additional Fee for this Amendment \$1,134.00 *If the entry in column 2 is less than the entry in column 4, write "0" in column 5. **If the "Highest Number Previously Paid For" IN THIS SPACE is less than 20, write "20" in this space. ***If the "Highest Number Previously Paid For" IN THIS SPACE is less than 3, write "3" in this space. ☐ The following other fees are incurred by the accompanying papers. ☐ Other: Please charge Deposit Account No. 01-0519 in the name of Amgen Inc. in the amount of \$ 1,134.00. A duplicate copy of this petition is attached. If an additional extension of time is required, please consider this a petition therefore. In the Commissioner is hereby authorized to charge any additional fees which may be required by the accompanying papers, or credit any overpayment to Deposit Account No. 01-0519.

Please Send Future Correspondence To: U.S. Patent Operations/DRC

Dept. 430, M/S 27-4-A

AMGEN INC.

One Amgen Center Drive

Thousand Oaks, California 91320-1789

Daniel R. Curry Attorney for Applicants Registration No.: 32,727

Phone: (805) 447-8102 Date: March 5, 1998

CERTIFICATE OF MAILING

I hereby certify that this correspondence is being deposited with the United States Postal Commissioner for Patents, Washington, D.C. 20231, on the date appearing below.

March 5, 1998

THE

THE PATENT OFFICE IS HEREBY REQUESTED TO ACKNOWLEDGE RECION OF THE FOLLOWING DOCUMENTS BY DATE STAMPING AND RETURNING THIS POST CARD

Serial No.: 08/182,183 Applicants: Lin, et al. Filed: May 23, 1994

Examiner: Marianne P. Allen Group Art Unit No.: 1817

Title: Glial Cell Line-Derived Neurotrophic Factor

<u>1</u> pg <u>14</u> pgs Amendment Transmittal Letter + 1 copy

Response and Amendment

S-225E DRC/khh

Via First Class Mail

March 5, 1998

Amgen Inc. 1840 DeHavilland Drive Thousand Oaks, CA 91320-1789



Assistant Commissioner for Patents Washington DC 20231